Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 12—December 2009
Dispatch

Molecular Model of Prion Transmission to Humans

Michael JonesComments to Author , Darren Wight, Rona Barron, Martin Jeffrey, Jean C. Manson, Christopher Prowse, James W. Ironside, and Mark W. Head
Author affiliations: University of Edinburgh, Edinburgh, Scotland, UK (M. Jones, D. Wight, R. Barron, J. Manson, J.W. Ironside, M.W. Head), Veterinary Laboratory Agency, Edinburgh (M. Jeffrey); Scottish National Blood Transfusion Service, Edinburgh (C. Prowse)

Main Article

Figure 1

Amplification of PrPd by PMCA from bovine BSE, ovine scrapie, experimental ovine BSE, and human vCJD brain homogenates in substrate homogenates prepared from humanized transgenic mouse brain tissue expressing PrP of each human prion protein gene codon 129 (PRNP-129) genotype. A) Amplification of each PrPd type, as determined by Western blotting using MAb 6H4 to detect PrPres after limited proteinase K digestion, in a PRNP-129MM substrate (top panel, 3-min exposure), a PRNP-129MV substrate (middl

Figure 1. Amplification of PrPd by PMCA from bovine BSE, ovine scrapie, experimental ovine BSE, and human vCJD brain homogenates in substrate homogenates prepared from humanized transgenic mouse brain tissue expressing PrP of each human prion protein gene codon 129 (PRNP-129) genotype. A) Amplification of each PrPd type, as determined by Western blotting using MAb 6H4 to detect PrPres after limited proteinase K digestion, in a PRNP-129MM substrate (top panel, 3-min exposure), a PRNP-129MV substrate (middle panel, 3-min exposure), and a PRNP-129VV substrate (bottom panel, 3-min exposure). B) Amplification of each PrPd type, as determined by Western blotting using MAb 3F4 to detect PrPres derived from human PrP after limited proteinase K digestion, in a PRNP-129MM substrate (top panel, 30-s exposure), a PRNP-129MV substrate (middle panel, 3-min exposure), and a PRNP-129VV substrate (bottom panel, 10-min exposure). Limited proteinase K digestion and Western blotting were conducted out as previously described (11). MAb 6H4 (Prionics, Schlieren-Zurich, Switzerland) and MAb 3F4 (Dako, Ely, Cambridgeshire, UK) were used at a final concentration of 50 ng/mL. PrPd, disease-associated prion protein; PMCA, protein misfolding cyclic amplification; BSE, bovine spongiform encephalopathy; vCJD, variant Creutzfeldt-Jakob disease; MAb, monoclonal antibody; PrPres, protease-resistant prion protein; MM, methionine homozygous; MV, methionine/valine heterozygous; VV, valine homozygous. Values on the left are in kilodaltons.

Main Article

References
  1. Bruce  ME. TSE strain variation. Br Med Bull. 2003;66:99–108. DOIPubMedGoogle Scholar
  2. Prusiner  SB. Prions. Proc Natl Acad Sci U S A. 1998;95:13363–83. DOIPubMedGoogle Scholar
  3. Collinge  J, Clark  AR. A general model of prion strains and their pathogenicity. Science. 2007;318:930–6. DOIPubMedGoogle Scholar
  4. Will  RG, Ironside  JW, Zeidler  M, Cousens  SN, Estibeiro  K, Alperovitch  A, Lancet. 1996;347:921–5. DOIPubMedGoogle Scholar
  5. Collinge  J, Sidle  KC, Meads  J, Ironside  J, Hill  AF. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature. 1996;383:685–90. DOIPubMedGoogle Scholar
  6. Head  MW, Bunn  TJ, Bishop  MT, McLoughlin  V, Lowrie  S, McKimmie  J, Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991–2002. Ann Neurol. 2004;55:851–9. DOIPubMedGoogle Scholar
  7. Eloit  M, Adjou  K, Coulpier  M, Fontaine  JJ, Hamel  R, Lilin  T, BSE agent signatures in a goat. Vet Rec. 2005;156:523–4.PubMedGoogle Scholar
  8. Supattapone  S. Prion protein conversion in vitro. J Mol Med. 2004;82:348–56. DOIPubMedGoogle Scholar
  9. Saborio  GP, Permanne  B, Soto  C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 2001;411:810–3. DOIPubMedGoogle Scholar
  10. Jones  M, Peden  AH, Prowse  CV, Groner  A, Manson  JC, Turner  ML, In vitro amplification and detection of variant Creutzfeldt-Jakob disease PrPSc. J Pathol. 2007;213:21–6. DOIPubMedGoogle Scholar
  11. Yull  HM, Ritchie  DL, Langeveld  JP, van Zijderveld  FG, Bruce  ME, Ironside  JW, Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease. Am J Pathol. 2006;168:151–7. DOIPubMedGoogle Scholar
  12. Jeffrey  M, Martin  S, Thomson  JR, Dingwall  WS, Begara-McGorum  I, Gonzalez  L. Onset and distribution of tissue prp accumulation in scrapie-affected Suffolk sheep as demonstrated by sequential necropsies and tonsillar biopsies. J Comp Pathol. 2001;125:48–57. DOIPubMedGoogle Scholar
  13. Gonzalez  L, Chianini  F, Martin  S, Siso  S, Gibbard  L, Reid  HW, Comparative titration of experiment ovine BSE infectivity in sheep and mice. J Gen Virol. 2007;88:714–7. DOIPubMedGoogle Scholar
  14. Bishop  MT, Hart  P, Aitchison  L, Baybutt  HN, Plinston  C, Thomson  V, Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol. 2006;5:393–8. DOIPubMedGoogle Scholar
  15. Manson  JC, Cancellotti  E, Hart  P, Bishop  MT, Barron  RM. The transmissible spongiform encephalopathies: emerging and declining epidemics. Biochem Soc Trans. 2006;34:1155–8. DOIPubMedGoogle Scholar

Main Article

Page created: December 09, 2010
Page updated: December 09, 2010
Page reviewed: December 09, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external